Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure

International Journal of Cardiology

Volumn 159, Issue 3, 2012, Pages 225-229

  Bonios, Michael J ^a   Terrovitis, John V ^a   Drakos, Stavros G ^a   Katsaros, Fotis ^a   Pantsios, Chris ^a   Nanas, Serafim N ^a   Kanakakis, John ^a   Alexopoulos, George ^a   Toumanidis, Savvas ^a   Anastasiou Nana, Maria ^a   Nanas, John N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Dobutamine; Heart failure; Inotrope therapy; Levosimendan

Indexed keywords

AMIODARONE; DOBUTAMINE; LEVOSIMENDAN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; END STAGE HEART FAILURE; FEMALE; HEART FAILURE; HEART INDEX; HUMAN; INOTROPISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84865449305     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.03.013     Document Type: Article

References (40)

1. D. Levy, S. Kenchaiah, and M.G. Larson Long-term trends in the incidence of and survival with heart failure N Engl J Med 347 2002 1397 1402
2. K. Dickstein, A. Cohen-Solal, and G. Filippatos ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 2008 933 989
3. S.A. Hunt, W.T. Abraham, and M.H. Chin 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 e391 e479
4. S.G. Drakos, E.I. Charitos, S.N. Nanas, and J.N. Nanas Ventricular-assist devices for the treatment of chronic heart failure Expert Rev Cardiovasc Ther 5 2007 571 584
5. G.M. Felker, and C.M. O'Connor Inotropic therapy for heart failure: an evidence-based approach Am Heart J 142 2001 393 401
6. J.B. Young Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Pharmacotherapy 16 1996 78S 84S
7. S. Sasayama What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther 6 1992 15 18
8. S. Thackray, J. Easthaugh, N. Freemantle, and J.G. Cleland The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis Eur J Heart Fail 4 2002 515 529
9. J.N. Nanas, D.A. Kontoyannis, and G.P. Alexopoulos Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure Chest 119 2001 1173 1178
10. J.N. Nanas, E.P. Tsagalou, and J. Kanakakis Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study Chest 125 2004 1198 1204
11. S.G. Drakos, J.V. Kanakakis, and S. Nanas Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure J Cardiovasc Pharmacol 53 2009 157 161
12. J.C. Kaski, L.A. Girotti, H. Messuti, B. Rutitzky, and M.B. Rosenbaum Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone Circulation 64 1981 273 279
13. B.N. Singh Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy Am J Cardiol 72 1993 114F 124F
14. E.P. Tsagalou, P. Gounopoulos, and J.V. Terrovitis Amiodarone attenuates the proarrhythmic effects of dobutamine in patients with advanced congestive heart failure Hellenic J Cardiol 50 2009 193 198
15. C.L. D'Amico Cardiac transplantation: patient selection in the current era J Cardiovasc Nurs 20 2005 S4 S13
16. F. Oliva, R. Latini, and A. Politi Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial Am Heart J 138 1999 247 253
17. A. Elis, T. Bental, O. Kimchi, M. Ravid, and M. Lishner Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study Clin Pharmacol Ther 63 1998 682 685
18. H.H. Erlemeier, W. Kupper, and W. Bleifeld Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance Cardiovasc Drugs Ther 6 1992 391 398
19. J.N. Nanas, E.P. Tsagalou, and S.N. Nanas Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy Int J Cardiol 108 2006 237 243
20. E.P. Tsagalou, M.I. Anastasiou-Nana, and J.V. Terrovitis The long-term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease Int J Cardiol 108 2006 244 250
21. A. Mebazaa, M.S. Nieminen, and G.S. Filippatos Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE Eur J Heart Fail 11 2009 304 311
22. M. Metra, E. Eichhorn, and W.T. Abraham Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials Eur Heart J 30 2009 3015 3026
23. S.F. Shakar, W.T. Abraham, and E.M. Gilbert Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure J Am Coll Cardiol 31 1998 1336 1340
24. S. Adamopoulos, M. Piepoli, and F. Qiang Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure Lancet 345 1995 344 349
25. C.V. Leier, and P.F. Binkley Parenteral inotropic support for advanced congestive heart failure Prog Cardiovasc Dis 41 1998 207 224
26. D.V. Unverferth, R.D. Magorien, R. Altschuld, A.J. Kolibash, R.P. Lewis, and C.V. Leier The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy Am Heart J 106 1983 29 34
27. P.F. Binkley, D.B. Van Fossen, E. Nunziata, D.V. Unverferth, and C.V. Leier Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure J Am Coll Cardiol 15 1990 1127 1135
28. D.V. Unverferth, C.V. Leier, and R.D. Magorien Improvement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study J Pharmacol Exp Ther 215 1980 527 532
29. P.C. Colombo, J.E. Banchs, and S. Celaj Endothelial cell activation in patients with decompensated heart failure Circulation 111 2005 58 62
30. D.A. Kass, and R.J. Solaro Mechanisms and use of calcium-sensitizing agents in the failing heart Circulation 113 2006 305 315
31. S. Antila, S. Sundberg, and L.A. Lehtonen Clinical pharmacology of levosimendan Clin Pharmacokinet 46 2007 535 552
32. D.P. Figgitt, P.S. Gillies, and K.L. Goa Levosimendan Drugs 61 2001 613 627 discussion 628-9
33. J.N. Nanas, P.P. Papazoglou, and J.V. Terrovitis Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone Am J Cardiol 94 2004 1329 1332
34. F. Follath, J.G. Cleland, and H. Just Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 2002 196 202
35. A. Mebazaa, M.S. Nieminen, and M. Packer Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial Jama 297 2007 1883 1891
36. J.T. Parissis, S. Adamopoulos, and D. Farmakis Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart 92 2006 1768 1772
37. S. Adamopoulos, J.T. Parissis, and E.K. Iliodromitis Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure Am J Cardiol 98 2006 102 106
38. S. Mavrogeni, G. Giamouzis, and E. Papadopoulou A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure J Card Fail 13 2007 556 559
39. C. Nakajima-Takenaka, S. Sakata, and S. Kato Detrimental effects after dobutamine infusion on rat left ventricular function: mechanical work and energetics Exp Physiol 90 2005 635 644
40. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2